Nanoparticle isoflavone compositions and methods of making and using the same
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
1. A method of treating acute radiation syndrome, the method comprising:
identifying a subject that has experienced exposure to radiation of at least 0.3 Gray or 30 rads; and
treating the said subject by administering to the subject a therapeutically effective amount of a genistein formulation,
wherein the genistein formulation comprises:
nanoparticulate genistein, and
one or more pharmaceutically acceptable excipients forming a suspension medium,
wherein the one or more pharmaceutically acceptable excipients include a water soluble polymer comprising a polyvinylpyrrolidone (PVP),
wherein the nanoparticulate genistein exhibits a D (0.50) of 0.5 μm or less and no particles measure greater than 2 μm and the one or more pharmaceutically acceptable excipients are selected such that the nanoparticulate genistein is suspended within the suspension medium, and
wherein the genistein formulation administered to the subject has a nanoparticulate genistein concentration selected from a concentration of between about 250 mg/mL and about 500 mg/mL, a concentration of between about 250 mg/mL and about 400 mg/mL, a concentration of between about 250 mg/mL and about 350 mg/mL, and a concentration of between about 275 mg/mL and about 325 mg/mL.
2. The method of claim 1 , wherein the one or more pharmaceutically acceptable excipients further include at least one of a nonionic surfactant, a diluent, and a buffer.
3. The method of claim 1 , wherein the one or more pharmaceutically acceptable excipients further include a nonionic surfactant.
4. The method of claim 2 , wherein the nonionic surfactant is present in an amount ranging from about 0.01% to about 10% by weight (w/w).
5. The method of claim 4 , wherein the amount of nonionic surfactant is selected from about 0.01% to about 10% (w/w), about 0.1% to about 10% (w/w), about 0.2% to about 5% (w/w), about 0.2% to about 1% (w/w), about 0.2% to about 1% (w/w), about 0.2% to about 0.6% (w/w), and about 0.2% to about 0.8% (w/w), and the amount of water soluble polymer is selected from about 0.5% to about 15% (w/w), about 1% to about 10% (w/w), about 5% to about 15% (w/w), about 10% to about 15% (w/w), about 12% to about 15% (w/w), about 1% to about 8% (w/w), and about 1% to about 5% (w/w).
6. The method of claim 1 , wherein the amount of water soluble polymer is present in an amount selected from a range of about 0.5% to about 15% (w/w), about 1% to about 10% (w/w), about 5% to about 15% (w/w), about 10% to about 15% (w/w), about 12% to about 15% (w/w), about 1% to about 8% (w/w), and about 1% to about 5% (w/w).
7. The method of claim 1 , wherein the nanoparticulate genistein is present in the genistein formulation at an amount ranging up to about 85% (w/w).
8. The method of claim 7 , wherein the nanoparticulate genistein is present in the genistein formulation at an amount selected from a range of about 40% to about 75% (w/w), a range of about 40% to about 65% (w/w), a range of about 40% to about 50% (w/w), a range of about 50% to about 75% (w/w), and a range of about 50% to about 65% (w/w).
9. The method of claim 2 , wherein the buffer is a sodium phosphate buffer.
10. The method of claim 2 , wherein the diluent is a sodium chloride solution.
11. The method of claim 1 , wherein the genistein formulation exhibits a pH selected from a range of about 2 to about 12, about 4 to about 8, and about 5 to about 7.
12. A method of prophylactically treating exposure to radiation resulting from a therapeutic or diagnostic procedure, the method comprising:
identifying a subject scheduled for a therapeutic or diagnostic procedure requiring exposure to radiation; and
prior to the therapeutic or diagnostic procedure, administering to the subject a therapeutically effective amount of a genistein formulation,
wherein the genistein formulation comprises:
nanoparticulate genistein, and
one or more pharmaceutically acceptable excipients forming a suspension medium,
wherein the one or more pharmaceutically acceptable excipients include a water soluble polymer comprising a polyvinylpyrrolidone (PVP),
wherein the nanoparticulate genistein exhibits a D (0.50) of 0.5 μm or less and no particles measure greater than 2 μm and the one or more pharmaceutically acceptable excipients are selected such that the nanoparticulate genistein is suspended within the suspension medium, and
wherein the genistein formulation administered to the subject has a nanoparticulate genistein concentration selected from a concentration of between about 250 mg/mL and about 500 mg/mL, a concentration of between about 250 mg/mL and about 400 mg/mL, a concentration of between about 250 mg/mL and about 350 mg/mL, and a concentration of between about 275 mg/mL and about 325 mg/mL.
13. The method of claim 12 , wherein the one or more pharmaceutically acceptable excipients further include at least one of a nonionic surfactant, a diluent, and a buffer.
14. The method of claim 12 , wherein the one or more pharmaceutically acceptable excipients further include a nonionic surfactant.
15. The method of claim 13 , wherein the nonionic surfactant is present in an amount ranging from about 0.01% to about 10% by weight (w/w).
16. The method of claim 15 , wherein the amount of nonionic surfactant is selected from about 0.01% to about 10% (w/w), about 0.1% to about 10% (w/w), about 0.2% to about 5% (w/w), about 0.2% to about 1% (w/w), about 0.2% to about 1% (w/w), about 0.2% to about 0.6% (w/w), and about 0.2% to about 0.8% (w/w), and the amount of water soluble polymer is selected from about 0.5% to about 15% (w/w), about 1% to about 10% (w/w), about 5% to about 15% (w/w), about 10% to about 15% (w/w), about 12% to about 15% (w/w), about 1% to about 8% (w/w), and about 1% to about 5% (w/w).
17. The method of claim 12 , wherein the amount of water soluble polymer is present in an amount selected from a range of about 0.5% to about 15% (w/w), about 1% to about 10% (w/w), about 5% to about 15% (w/w), about 10% to about 15% (w/w), about 12% to about 15% (w/w), about 1% to about 8% (w/w), and about 1% to about 5% (w/w).
18. The method of claim 12 , wherein the nanoparticulate genistein is present in the genistein formulation at an amount ranging up to about 85% (w/w).
19. The method of claim 18 , wherein the nanoparticulate genistein is present in the genistein formulation at an amount selected from a range of about 40% to about 75% (w/w), a range of about 40% to about 65% (w/w), a range of about 40% to about 50% (w/w), a range of about 50% to about 75% (w/w), and a range of about 50% to about 65% (w/w).
20. The method of claim 13 , wherein the buffer is a sodium phosphate buffer.
21. The method of claim 13 , wherein the diluent is a sodium chloride solution.
22. The method of claim 12 , wherein the genistein formulation exhibits a pH selected from a range of about 2 to about 12, about 4 to about 8, and about 5 to about 7.
23. The method of claim 12 , wherein the PVP is povidone K17.
24. The method of claim 12 , wherein in the event the subject experiences an exposure to radiation, continuing to administer therapeutically effective amounts of the genistein formulation to the subject after the subject experiences radiation exposure.
25. A method of preventing the onset of acute radiation syndrome, the method comprising:
identifying a subject at risk of exposure to radiation greater than 0.7 Gray or 70 rads through close proximity to radioactive material;
prior to the subject being exposed to radiation, administering to the subject a therapeutically effective amount of a genistein formulation,
wherein the genistein formulation comprises:
nanoparticulate genistein, and
one or more pharmaceutically acceptable excipients forming a suspension medium,
wherein the one or more pharmaceutically acceptable excipients include a water soluble polymer comprising a polyvinylpyrrolidone (PVP),
wherein the nanoparticulate genistein exhibits a D (0.50) of 0.5 μm or less and no particles measure greater than 2 μm and the one or more pharmaceutically acceptable excipients are selected such that the nanoparticulate genistein is suspended within the suspension medium, and
wherein the genistein formulation administered to the subject has a nanoparticulate genistein concentration selected from a concentration of between about 250 mg/mL and about 500 mg/mL, a concentration of between about 250 mg/mL and about 400 mg/mL, a concentration of between about 250 mg/mL and about 350 mg/mL, and a concentration of between about 275 mg/mL and about 325 mg/mL; and
after the subject has been exposed to radiation, continuing to administer therapeutically effective amounts of the genistein formulation to the subject.